Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...

A "sub-study" of a late-stage clinical trial found the drug, obicetrapib, significantly reduced levels of a certain type of ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...

The location of the European Medicines Agency after Brexit is to be decided today, as representatives of member states vote in a complex secret ballot that could end with a coin toss. A meeting of ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple myeloma.

Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progression ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.